These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7202826)

  • 21. A prostacyclin-sparing effect of indobufen vs. aspirin.
    De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
    Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiaggregant effect of indobufen (K3920) measured by the platelet aggregate filtration pressure test (PAFP).
    Visonà A; Davanzo S; Bruno R; Pagnan A
    J Int Med Res; 1983; 11(1):10-4. PubMed ID: 6832462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet activity and tolerance of indobufen (K3920) in cerebrovascular disease: a therapeutic approach.
    Carrieri P; Orefice G; La Pia S; Indaco A; D'Acunio F; Iadevaia V
    Pharmatherapeutica; 1983; 3(6):410-6. PubMed ID: 6353432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen.
    Fortunato JS; Pinheiro MJ; Monteiro MC; Rodrigues MA; Amaral I
    J Int Med Res; 1991; 19(4):305-17. PubMed ID: 1916004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of acetylsalicylic acid. Dipyridamole and K 3920 on the secretion of platelet factor 4.
    Akman N
    Haematologica; 1980 Aug; 65(4):546-51. PubMed ID: 6774930
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of ticlopidine and indobufen on platelet aggregation induced by A23187 and adrenaline in the presence of different anticoagulants.
    Cimminiello C; Milani M; Uberti T; Arpaia G; Bonfardeci G
    J Int Med Res; 1989; 17(6):514-20. PubMed ID: 2516825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man.
    De Caterina R; Sicari R; Yan A; Bernini W; Giannessi D; Lazzerini G; Efthymiopoulos C; Strolin-Benedetti M
    Thromb Haemost; 1992 Feb; 67(2):258-63. PubMed ID: 1621247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Long-term effects of indobufen on several parameters of blood platelet function in subjects at thrombotic risk].
    Di Blasi S; Pintacuda S; Ferotti N; Lo Coco L; Muratore A; Russo G; Di Blasi U; D'Alessandro M; Morici G; Fornaciari M
    G Clin Med; 1990 Dec; 71(12):727-31. PubMed ID: 2150826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
    Yang M; Ye Z; Mei L; Ullah I; Tan C; Wang G; Gu Q; Lu Y; Abdus S; Shi L; Gong X; Bai J; Eikelboom JW; Li C
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1815-1823. PubMed ID: 34331551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Activation and functions of blood platelets in patients with diabetes mellitus type 1 before and during the treatment with indobufen].
    Dmoszyńska-Giannopoulou A; Sokołowska B; Ledwozyw A
    Pol Arch Med Wewn; 1990 Mar; 83(3):97-103. PubMed ID: 2216938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of indobufen on leukocyte-dependent thrombocyte aggregation in patients with ischemic heart disease].
    Liusov VA; Diukov IV; Uteshev DV
    Kardiologiia; 1993; 33(4):22-3. PubMed ID: 7933785
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of spontaneous platelet aggregation and adhesion by indobufen (K 3920). A randomized, double-blind crossover study on platelet, coagulation and fibrinolysis function tests.
    Nenci GG; Berrettini M; Iadevaia V; Parise P; Ballatori E
    Pharmatherapeutica; 1982; 3(3):188-94. PubMed ID: 7134226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk.
    Mannucci L; Maderna P; Colli S; Lavezzari M; Sirtori CR; Tremoli E
    Thromb Res; 1987 Nov; 48(4):417-26. PubMed ID: 3445229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of age on the pharmacokinetics of indobufen.
    Savazzi GM; Castiglioni A; Cavatorta A; Garini G; Montanari M; Borghetti A
    Int J Clin Pharmacol Ther Toxicol; 1986 May; 24(5):265-9. PubMed ID: 3733275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.
    Davì G; Patrono C; Catalano I; Custro N; Giammarresi C; Ganci A; Cosentino F; Notarbartolo A
    Arterioscler Thromb; 1993 Sep; 13(9):1346-9. PubMed ID: 8364018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment with indobufen of platelet hyperaggregation in a group of patients with vascular diseases].
    Barbieri U; Cappelli S; Zaniol P; Righi A; Artusi P; Scorrano M
    Minerva Med; 1991; 82(1-2):63-7. PubMed ID: 2000177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic effect of indobufen in an experimental model of arterio-arterial microanastomosis in the rat.
    Carrieri P; Donzelli R; Orefice G; Cerillo A; Volpentesta G; Tayana G
    Thromb Res; 1987 Feb; 45(3):195-9. PubMed ID: 3660337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergism between collagen-adenosine diphosphate and collagen-epinephrine in platelets' aggregation: different dose response relationships.
    Razi MS; Hameed W; Habib SS; Aslam M; Ashraf R
    J Pak Med Assoc; 2009 Jun; 59(6):368-71. PubMed ID: 19534370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Assessment of speed of an anti-platelet effect after two different doses of acetylsalicylic acid by flocculation].
    Malý M; Vojácek J; Hadacová I; Mates M; Hájek P; Durdil V
    Vnitr Lek; 2004 Jun; 50(6):428-33. PubMed ID: 15346635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term trial (6 months) of the platelet aggregation inhibitory activity and biological safety of indobufen in cerebrovascular patients.
    Mansi D; Majello L; Palma V; De Michele G; Buscaino GA
    Acta Neurol (Napoli); 1983 Dec; 5(6):447-55. PubMed ID: 6367383
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.